Ifinatamab Deruxtecan Tetap Menunjukkan Tingkat Respon Objektif yang Menjanjikan pada Pasien dengan Kanker Paru-paru Sel Kecil Tahap Lanjut dalam Uji Klinis Fase 2 IDeate-Lung01.
found on the surface of tumor cells and is associated with disease progression and poor prognosis in small cell lung cancer. Ifinatamab deruxtecan is a B7-H3 directed antibody drug conjugate that specifically targets this protein, potentially offering a new treatment option for patients with this challenging disease. The interim analysis of the IDeate-Lung01 trial showed … Baca Selengkapnya